Abliva AB (NEVPF)
0.01
0.00 (0.00%)
USD |
OTCM |
May 16, 16:00
Abliva Revenue (Quarterly): 0.0129M for Dec. 31, 2023
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 0.0129M |
| September 30, 2023 | |
| June 30, 2023 | |
| March 31, 2023 | |
| December 31, 2022 | |
| September 30, 2022 | 0.003M |
| June 30, 2022 | |
| March 31, 2022 | |
| December 31, 2021 | 0.0054M |
| September 30, 2021 | 0.0098M |
| June 30, 2021 | 0.0021M |
| March 31, 2021 | |
| December 31, 2020 | 0.0129M |
| September 30, 2020 | |
| June 30, 2020 | 0.01M |
| March 31, 2020 | 0.0008M |
| December 31, 2019 | 0.0051M |
| September 30, 2019 | |
| June 30, 2019 | 0.009M |
| March 31, 2019 | |
| December 31, 2018 | 0.0006M |
| September 30, 2018 | |
| June 30, 2018 | |
| March 31, 2018 | |
| December 31, 2017 |
| Date | Value |
|---|---|
| September 30, 2017 | |
| June 30, 2017 | |
| March 31, 2017 | 0.003M |
| December 31, 2016 | 0.0015M |
| September 30, 2016 | |
| June 30, 2016 | |
| March 31, 2016 | |
| December 31, 2015 | |
| September 30, 2015 | |
| June 30, 2015 | 0.2971M |
| March 31, 2015 | |
| December 31, 2014 | |
| September 30, 2014 | 1.03M |
| June 30, 2014 | |
| March 31, 2014 | |
| December 31, 2013 | |
| September 30, 2013 | |
| June 30, 2013 | 0.8141M |
| March 31, 2013 | |
| December 31, 2012 | |
| September 30, 2012 | |
| June 30, 2012 | |
| March 31, 2012 | |
| December 31, 2011 | 0.8237M |
| September 30, 2011 |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
0.0008M
Minimum
Mar 2020
0.0129M
Maximum
Dec 2020
0.0071M
Average
0.0072M
Median
Revenue (Quarterly) Benchmarks
| Karolinska Development AB | 0.0454M |
| Calliditas Therapeutics AB | 42.53M |
| Oncopeptides AB | 0.26M |
| Olink Holding AB | 28.75M |
| BioInvent International AB | 0.5729M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -2.377M |
| Total Expenses (Quarterly) | 2.598M |
| EPS Diluted (Quarterly) | -0.0019 |
| Enterprise Value | 7.716M |
| Profit Margin (Quarterly) | -18.42K% |
| Earnings Yield | -84.88% |
| Normalized Earnings Yield | -84.91 |